Compare NSTS & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NSTS | RLYB |
|---|---|---|
| Founded | 1921 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.9M | 89.2M |
| IPO Year | 2021 | 2021 |
| Metric | NSTS | RLYB |
|---|---|---|
| Price | $14.15 | $16.86 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 14.4K | 7.4K |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 6.16 |
| Revenue | $252,000.00 | ★ $858,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $2.75 |
| Revenue Growth | N/A | ★ 43.00 |
| 52 Week Low | $10.73 | $0.48 |
| 52 Week High | $14.19 | $17.57 |
| Indicator | NSTS | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 71.30 | N/A |
| Support Level | $13.70 | N/A |
| Resistance Level | $14.19 | N/A |
| Average True Range (ATR) | 0.05 | 0.00 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 85.00 | 0.00 |
NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in market area of Lake County, Illinois and adjacent communities.
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.